AstraZeneca (AZN) Projected to Post Quarterly Earnings on Thursday

AstraZeneca (NASDAQ:AZN - Get Free Report) is projected to issue its quarterly earnings data before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of $1.10 per share and revenue of $14.19 billion for the quarter. Individual interested in listening to the company's earnings conference call can do so using this link.

AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping the consensus estimate of $1.01 by $0.03. The business had revenue of $13.57 billion for the quarter, compared to analysts' expectations of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business's quarterly revenue was up 18.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.87 EPS. On average, analysts expect AstraZeneca to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

AstraZeneca Price Performance

Shares of AstraZeneca stock traded down $0.48 during trading on Friday, reaching $70.76. 3,757,594 shares of the stock traded hands, compared to its average volume of 4,392,157. AstraZeneca has a 52-week low of $60.47 and a 52-week high of $87.68. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The business has a fifty day simple moving average of $67.08 and a two-hundred day simple moving average of $73.89. The company has a market capitalization of $219.43 billion, a price-to-earnings ratio of 33.86, a P/E/G ratio of 1.17 and a beta of 0.46.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. UBS Group upgraded AstraZeneca from a "sell" rating to a "neutral" rating in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a "sell" rating to a "hold" rating in a report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, AstraZeneca currently has a consensus rating of "Buy" and an average target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.